Similar articles

• Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

  Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Manosuthi W, et al. Clin Infect Dis. 2007 Jan 1;44(1):141-4. doi: 10.1086/510078. Epub 2006 Nov 21. Clin Infect Dis. 2007. PMID: 17143831
• A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

  Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team. Manosuthi W, et al. Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114. Clin Infect Dis. 2009. PMID: 19438397 Clinical Trial.
• Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.

  Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K. Avihingsanon A, et al. Antivir Ther. 2008;13(4):529-36. Antivir Ther. 2008. PMID: 18672531 Clinical Trial.
• Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.

  Maartens G, Decloedt E, Cohen K. Maartens G, et al. Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Antivir Ther. 2009. PMID: 20032533 Review.
• [Combined antiretroviral therapy with nevirapine of HIV-infected adults].

  Kravchenko AV. Kravchenko AV. Ter Arkh. 2004;76(11):68-71. Ter Arkh. 2004. PMID: 15658542 Review. Russian. No abstract available.